US Markets
AZN

S&P 500, Nasdaq at record highs on COVID-19 treatment hopes

Credit: REUTERS/MIKE SEGAR

The S&P 500 and Nasdaq scaled new highs on Monday as a U.S. approval for the emergency use of blood plasma in COVID-19 patients lifted treatment hopes and spurred bets of a quicker economic recovery.

By Medha Singh and Devik Jain

Aug 24 (Reuters) - The S&P 500 and Nasdaq scaled new highs on Monday as a U.S. approval for the emergency use of blood plasma in COVID-19 patients lifted treatment hopes and spurred bets of a quicker economic recovery.

The U.S. Food and Drug Administration's decision to use antibody-rich plasma from recovered patients was hailed by President Donald Trump, a day after he accused it of impeding the rollout of treatments for political reasons.

The World Health Organization, however, was cautious about endorsing the treatment, citing "low quality" evidence that it works.

"The market is responding favorably to the possibilities of being able to inject antibodies as another form of combating the virus," said Sam Stovall, chief investment strategist at CFRA Research in New York.

Aiding market sentiment was a report the Trump administration is considering fast-tracking an experimental COVID-19 vaccine developed by AstraZeneca Plc AZN.L and Oxford University for use in the United States before election.

The push for plasma treatment and the speeding up of a vaccine candidate came in the run up to the Republican National Convention, which began on Monday. President Trump secured sufficient votes to lead his party for four more years, kicking off the final sprint to Nov. 3 Election Day.

Ahead of the 4-for-1 share split on Friday, Apple Inc AAPL.O gained 2% to cross $500 per share for the first time, providing the biggest boost to the three main indexes.

Economically-sensitive energy .SPNY, financials .SPSY and materials .SPLRCM, which are lagging the broader market this year, advanced more than any other major S&P sector.

In the previous session, the S&P 500 and Nasdaq closed at record levels, wrapping up four weeks of gains on bets that technology focused companies will emerge stronger and the economy will return to growth on monetary and fiscal support.

The Dow, however, is still about 5% below its February peak.

Meanwhile, the next phase of coronavirus government aid remained elusive as top Democrats and Republicans continued to blame each other for stalled talks on the legislation.

A key event this week would be the address by Federal Reserve Chair Jerome Powell at the Kansas City Fed's annual symposium, where he will talk on the monetary policy framework review.

At 12:34 p.m. ET, the Dow Jones Industrial Average .DJI was up 255.47 points, or 0.91%, at 28,185.80, the S&P 500 .SPX was up 23.11 points, or 0.68%, at 3,420.27. The Nasdaq Composite .IXIC was up 53.40 points, or 0.47%, at 11,365.20.

Advancing issues outnumbered decliners by a 2.64-to-1 ratio on the NYSE and by a 1.17-to-1 ratio on the Nasdaq.

The S&P index recorded 45 new 52-week highs and no new low, while the Nasdaq recorded 76 new highs and 33 new lows.

(Reporting by Medha Singh and Devik Jain in Bengaluru; Editing by Maju Samuel and Arun Koyyur)

((Medha.Singh@thomsonreuters.com; within U.S. +1646 223 8780, outside U.S. +91 80 6749 1130; Twitter: https://twitter.com/medhasinghs))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN AAPL SPX

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More